Chronic Myelomonocytic Leukemia Recruiting Phase 2 Trials for Dasatinib (DB01254)

Also known as: Chronic myelomonocytic leukaemia / Chronic myelomonocytic leukemia with failed remission / Leukemia, Myelomonocytic, Chronic

IndicationStatusPhase
DBCOND0028572 (Chronic Myelomonocytic Leukemia)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01620216Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous LeukemiaTreatment